Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Clinical outcome measures in multiple sclerosis.

Maria Pia Amato1, Emilio Portaccio

  • 1Department of Neurology, University of Florence, Florence, Italy. mariapia.amato@unifi.it

Journal of the Neurological Sciences
|March 23, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Profiling the long-term risk of severe adverse events in a cohort of multiple sclerosis patients treated with different treatment sequences: Results from the Italian Multiple Sclerosis and Related Disorders Registry (I-MS&RD) (ProSA study).

Multiple sclerosis (Houndmills, Basingstoke, England)·2026
Same author

Cognitive impairment in multiple sclerosis: Where do we stand today?

Multiple sclerosis (Houndmills, Basingstoke, England)·2026
Same author

Perturbational complexity index detects subclinical cortical changes in early multiple sclerosis.

Clinical neurophysiology : official journal of the International Federation of Clinical Neurophysiology·2026
Same author

A predictive tool for early treatment escalation after initiation of moderate-efficacy therapy in pediatric-onset multiple sclerosis.

Multiple sclerosis (Houndmills, Basingstoke, England)·2026
Same author

Use of High-Efficacy Therapy in Children With Multiple Sclerosis to Prevent Long-Term Disability.

Neurology·2026
Same author

Reduced Childhood Outdoor Exposure Raises Pediatric Multiple Sclerosis (PedMS) Risk.

Neurology and therapy·2026

Accurately measuring multiple sclerosis (MS) clinical impact is vital for evaluating new treatments and guiding patient care. Current outcome measures, categorized by data source (neurological exam, functional tests, patient reports, or hybrid), each have pros and cons.

Area of Science:

  • Neurology
  • Clinical Trials
  • Biostatistics

Background:

  • Quantifying the clinical impact of multiple sclerosis (MS) is essential for assessing experimental therapies and optimizing patient care.
  • Current outcome measures for MS are diverse and fall into distinct categories.

Purpose of the Study:

  • To review and discuss the advantages and disadvantages of various clinical outcome measures used in multiple sclerosis.
  • To highlight the need for ideal measurement tools in MS clinical research and practice.

Main Methods:

  • Categorization of MS clinical outcome measures into four main groups based on data source: objective neurological examination, quantitative neurological function tests, patient/family-reported information, and hybrid measures.
  • Discussion of specific examples within each category, including the Expanded Disability Status Scale, Multiple Sclerosis Functional Composite, and quality of life instruments.

Related Experiment Videos

Main Results:

  • No single outcome measure has been identified as ideal for multiple sclerosis.
  • Each category of measurement tool possesses unique strengths and limitations.

Conclusions:

  • The selection of an appropriate outcome measure in multiple sclerosis depends on the specific clinical context and research question.
  • Further development and validation of measurement tools are needed to comprehensively capture the clinical impact of MS.